These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9406051)

  • 1. Detection of a common mutation in factor V gene responsible for resistance to activate protein C causing predisposition to thrombosis.
    Ferreira-Gonzalez A; Fisher LM; Lehman CM; Langley MH; Lofland DH; Xia Q; Nguyen NX; Modesto D; Willoughby JB; Wilkinson DS; Garrett CT
    J Clin Lab Anal; 1997; 11(6):328-35. PubMed ID: 9406051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modification of the ProC Global assay using dilution of patient plasma in factor V-depleted plasma as a screening assay for factor V Leiden mutation.
    Quincampoix JC; Legarff M; Rittling C; Andiva S; Toulon P
    Blood Coagul Fibrinolysis; 2001 Oct; 12(7):569-76. PubMed ID: 11685046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening.
    Ridker PM; Miletich JP; Hennekens CH; Buring JE
    JAMA; 1997 Apr 23-30; 277(16):1305-7. PubMed ID: 9109469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor V R506Q gene mutation analysis by PCR-RFLP: optimization, comparison with functional testing for resistance to activated protein C, and establishment of cell line controls.
    Voelkerding KV; Wu L; Williams EC; Hoffman SM; Sabatini LM; Borcherding WR; Huber S
    Am J Clin Pathol; 1996 Jul; 106(1):100-6. PubMed ID: 8701917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated protein C resistance assay performance: improvement by sample dilution with factor V-deficient plasma.
    Strobl FJ; Hoffman S; Huber S; Williams EC; Voelkerding KV
    Arch Pathol Lab Med; 1998 May; 122(5):430-3. PubMed ID: 9593344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular detection of a common mutation in coagulation factor V causing thrombosis via hereditary resistance to activated protein C.
    Liu XY; Nelson D; Grant C; Morthland V; Goodnight SH; Press RD
    Diagn Mol Pathol; 1995 Sep; 4(3):191-7. PubMed ID: 7493138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudo-homozygous activated protein C resistance due to coinheritance of heterozygous factor V Leiden mutation and type I factor V deficiency. Variable expression when analyzed by different activated protein C resistance functional assays.
    Delahousse B; Iochmann S; Pouplard C; Fimbel B; Charbonnier B; Gruel Y
    Blood Coagul Fibrinolysis; 1997 Nov; 8(8):503-9. PubMed ID: 9491268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
    Baig MA
    Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analytical evaluation of primer engineered multiplex polymerase chain reaction-restriction fragment length polymorphism for detection of factor V Leiden and prothrombin G20210A.
    Huber S; McMaster KJ; Voelkerding KV
    J Mol Diagn; 2000 Aug; 2(3):153-7. PubMed ID: 11229520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation.
    Bontempo FA; Hassett AC; Faruki H; Steed DL; Webster MW; Makaroun MS
    J Vasc Surg; 1997 Feb; 25(2):271-5; discussion 276. PubMed ID: 9052561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA; Fox EA; Longtine JA; Dorfman DM
    Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The predictability of factor V Leiden (FV:Q(506)) gene mutation via clotting-based diagnosis of activated protein C resistance.
    Sayinalp N; Haznedaroğlu IC; Aksu S; Büyükaşik Y; Göker H; Parlak H; Ozcebe OI; Kirazli S; Dündar SV; Gürgey A
    Clin Appl Thromb Hemost; 2004 Jul; 10(3):265-70. PubMed ID: 15247984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clinical application of a new specific functional assay to detect the factor V(Leiden) mutation associated with activated protein C resistance.
    van Oerle R; van Pampus L; Tans G; Rosing J; Hamulyák K
    Am J Clin Pathol; 1997 May; 107(5):521-6. PubMed ID: 9128263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance to activated protein C and a novel factor V gene mutation.
    Voelkerding KV
    Clin Lab Med; 1996 Mar; 16(1):169-86. PubMed ID: 8867589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 2-year retrospective analysis of laboratory testing for activated protein C resistance with a factor V-corrected activated partial thromboplastin time-based method.
    De Bel AV; Van der Cruyssen GA; Devreese KM
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):155-60. PubMed ID: 16479199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activated protein C resistance--a major risk factor for thrombosis.
    Rosén SB; Sturk A
    Eur J Clin Chem Clin Biochem; 1997 Jul; 35(7):501-16. PubMed ID: 9263726
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An evaluation of the Factor V Leiden mutation in a cohort of African-American pregnant women.
    Rose NC; Wang YL; Neubert AG; Roth NW; Li M; Wilson RB
    Prenat Diagn; 1998 Apr; 18(4):315-7. PubMed ID: 9602475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Japanese patients with various forms of thrombosis, and normal individuals.
    Zama T; Murata M; Ono F; Watanabe K; Watanabe R; Moriki T; Yokoyama K; Tokuhira M; Ikeda Y
    Int J Hematol; 1996 Dec; 65(1):71-8. PubMed ID: 8990627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APCR, factor V gene known and novel SNPs and adverse pregnancy outcomes in an Irish cohort of pregnant women.
    Sedano-Balbás S; Lyons M; Cleary B; Murray M; Gaffney G; Maher M
    BMC Pregnancy Childbirth; 2010 Mar; 10():11. PubMed ID: 20214832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.